Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

Dr Ajai Chari to Dr Callander: Switching to those newly diagnosed patients who are not transplant eligible or for whom transplant is not planned as initial therapy, Dr Callander, can you summarize the CEPHEUS data results presented at IMS and your key takeaways from this trial?

Resource Links

• OA-63 IMS 2024 CEPHEUS or (see page 11) 

Dr Ajai Chari to Dr Martin: How do CEPHEUS data compare to other quadruplet regimens in the non–transplant-eligible space, like Isa-VRd?

Resource Link

• OA-49 IMS 2024 IMROZ or (see page 12)
• Facon T et al. IMROZ Isa-VRd vs. VRd. ASCO 2024 Abstract

Resource Link:

• OA-52 IMS 2024 BENEFIT or (see page 13)
• Leleu X, et al. BENEFIT trial Isa-VRd vs. IsaRd. Nat Med. 2024.